Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Tomas Kiselak, and Peter Harwin filed a joint Form 4 on August 11, 2026, reporting stock option exercises in Apogee Therapeutics, Inc. (NASDAQ:APGE) dated August 7, 2026.

Key Highlights

  • Two option exercises: 31,838 shares were acquired via exercise of a stock option at $17.00 per share, and 10,370 shares were acquired via exercise of a stock option at $43.85 per share, both on August 7, 2026.
  • Post-transaction holdings: Fairmount Healthcare Fund II L.P. beneficially owns 340,855 shares of common stock following the reported transactions.
  • Additional indirect ownership: Tomas Kiselak and Peter Harwin each separately hold 51,166 shares of common stock indirectly.
  • Options fully exercised: Both stock options reported in Table II show zero derivative securities remaining following the transactions.
  • Vesting details: The $17.00 option represented the vested portion of a right to purchase 47,758 shares granted July 13, 2023, vesting in three approximately equal annual installments; the $43.85 option represented a right to purchase 10,370 shares granted June 5, 2024, vesting on its one-year anniversary.
  • Four reporting persons: The filing was made jointly by Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Tomas Kiselak, and Peter Harwin, all listed as directors of the issuer.

Fairmount-Affiliated Directors Report Option Exercises in Apogee Therapeutics

According to the filing, Fairmount Funds Management LLC serves as the investment manager for Fairmount Healthcare Fund II L.P., with Peter Harwin and Tomas Kiselak named as its managers. On August 7, 2026, two stock option exercises were reported, both coded "M" (exercise of in-the-money or at-the-money derivative security) under Table I. The first exercise involved 31,838 shares acquired at a price of $17.00 per share; the second involved 10,370 shares acquired at $43.85 per share. Both transactions are attributed indirectly to Fairmount Healthcare Fund II L.P.

The filing explains that the $17.00 option, with an expiration date of July 13, 2033, represented the vested portion of a total right to purchase 47,758 shares, vesting in three approximately equal annual installments beginning on the first anniversary of the July 13, 2023 grant date. The $43.85 option, expiring June 5, 2034, represented the full right to purchase 10,370 shares, which vested on the one-year anniversary of the June 5, 2024 grant date. Following the exercises, both derivative positions show zero remaining shares, according to the filing.

The filing notes that under Peter Harwin's arrangement with Fairmount Funds Management LLC, he held the options for one or more investment vehicles managed by the adviser and "was obligated to turn over to the Adviser any net cash or stock received from the options for the benefit of such Fairmount Fund." As a result, Harwin disclaimed beneficial ownership of the options and underlying common stock. Similarly, Fairmount Funds Management LLC, Harwin, and Kiselak each disclaim beneficial ownership of the reported securities "except to the extent of their pecuniary interest therein," according to the filing's explanatory footnotes.

What Was Disclosed

The joint Form 4 filed August 11, 2026 reports two stock option exercises by Fairmount-affiliated reporting persons in Apogee Therapeutics on August 7, 2026, resulting in Fairmount Healthcare Fund II L.P. holding 340,855 shares of common stock indirectly following the transactions.